• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

CLK2 的缺失使胶质瘤干细胞样细胞对 PI3K/mTOR 和 FGFR 抑制剂敏感。

Depletion of CLK2 sensitizes glioma stem-like cells to PI3K/mTOR and FGFR inhibitors.

作者信息

Park Soon Young, Mittal Sandeep, Dong Jianwen, Jeong Kangjin, Martinez-Ledesma Emmanuel, Piao Yuji, Khan Sabbir, Henry Verlene, Verhaak Roel Gw, Majd Nazanin, Balasubramaniyan Veerakumar, de Groot John F

机构信息

Department of Cell Developmental and Cancer Biology, Oregon Health and Science University Portland, Oregon, USA.

Department of Neuro-Oncology, The University of Texas MD Anderson Cancer Center Houston, Texas, USA.

出版信息

Am J Cancer Res. 2020 Nov 1;10(11):3765-3783. eCollection 2020.

PMID:33294266
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7716149/
Abstract

The Cdc2-like kinases (CLKs) regulate RNA splicing and have been shown to suppress cell growth. Knockdown of CLK2 was found to block glioma stem-like cell (GSC) growth through the AKT/FOXO3a/p27 pathway without activating mTOR and MAPK signaling, suggesting that these pathways mediate resistance to CLK2 inhibition. We identified CLK2 binding partners using immunoprecipitation assays and confirmed their interactions in GSCs. We then tested the cellular viability of several signaling inhibitors in parental and CLK2 knockdown GSCs. Our results demonstrate that CLK2 binds to 14-3-3τ isoform and prevents its ubiquitination in GSCs. Stable CLK2 knockdown increased PP2A activity and activated PI3K signaling. Treatment with a PI3K/mTOR inhibitor in CLK2 knockdown cells led to a modest reduction in cell viability compared to drug treatment alone at a lower dose. However, FGFR inhibitor in CLK2 knockdown cells led to a decrease in cell viability and increased apoptosis. Reduced expression of CLK2 in glioblastoma, in combination with FGFR inhibitors, led to synergistic apoptosis induction and cell cycle arrest compared to blockade or either kinase alone.

摘要

细胞周期蛋白依赖性激酶2样激酶(CLKs)调节RNA剪接,并已被证明可抑制细胞生长。研究发现,敲低CLK2可通过AKT/FOXO3a/p27途径阻断胶质瘤干细胞样细胞(GSC)的生长,而不激活mTOR和MAPK信号通路,这表明这些途径介导了对CLK2抑制的抗性。我们使用免疫沉淀试验鉴定了CLK2结合伴侣,并在GSCs中证实了它们的相互作用。然后,我们测试了几种信号抑制剂在亲本和CLK2敲低的GSCs中的细胞活力。我们的结果表明,CLK2与14-3-3τ亚型结合,并阻止其在GSCs中的泛素化。稳定敲低CLK2可增加PP2A活性并激活PI3K信号通路。与单独使用较低剂量的药物治疗相比,在CLK2敲低的细胞中用PI3K/mTOR抑制剂治疗导致细胞活力适度降低。然而,CLK2敲低细胞中的FGFR抑制剂导致细胞活力降低并增加凋亡。与单独阻断或任何一种激酶相比,胶质母细胞瘤中CLK2表达降低与FGFR抑制剂联合使用可导致协同诱导凋亡和细胞周期停滞。

相似文献

1
Depletion of CLK2 sensitizes glioma stem-like cells to PI3K/mTOR and FGFR inhibitors.CLK2 的缺失使胶质瘤干细胞样细胞对 PI3K/mTOR 和 FGFR 抑制剂敏感。
Am J Cancer Res. 2020 Nov 1;10(11):3765-3783. eCollection 2020.
2
Cdc2-like kinase 2 is a key regulator of the cell cycle via FOXO3a/p27 in glioblastoma.在胶质母细胞瘤中,细胞周期蛋白依赖性激酶样激酶2通过FOXO3a/p27是细胞周期的关键调节因子。
Oncotarget. 2016 May 3;7(18):26793-805. doi: 10.18632/oncotarget.8471.
3
Targeting of glioma stem-like cells with a parthenolide derivative ACT001 through inhibition of AEBP1/PI3K/AKT signaling.通过抑制 AEBP1/PI3K/AKT 信号通路靶向脑胶质瘤干细胞的角鲨烯衍生物 ACT001。
Theranostics. 2021 Jan 1;11(2):555-566. doi: 10.7150/thno.49250. eCollection 2021.
4
Combinatorial targeting of FGF and ErbB receptors blocks growth and metastatic spread of breast cancer models.成纤维细胞生长因子(FGF)受体与表皮生长因子受体(ErbB)的联合靶向作用可阻断乳腺癌模型的生长和转移扩散。
Breast Cancer Res. 2013 Jan 23;15(1):R8. doi: 10.1186/bcr3379.
5
Synergistic growth inhibition mediated by dual PI3K/mTOR pathway targeting and genetic or direct pharmacological AKT inhibition in human glioblastoma models.双重靶向 PI3K/mTOR 通路和遗传或直接药理学 AKT 抑制在人类脑胶质瘤模型中的协同生长抑制作用。
J Neurochem. 2020 May;153(4):510-524. doi: 10.1111/jnc.14899. Epub 2020 Jan 8.
6
Xihuang Pill-destabilized CD133/EGFR/Akt/mTOR cascade reduces stemness enrichment of glioblastoma via the down-regulation of SOX2.西黄丸破坏 CD133/EGFR/Akt/mTOR 级联减少通过下调 SOX2 富集神经胶质瘤干细胞。
Phytomedicine. 2023 Jun;114:154764. doi: 10.1016/j.phymed.2023.154764. Epub 2023 Mar 16.
7
NVP-BEZ235, a novel dual PI3K-mTOR inhibitor displays anti-glioma activity and reduces chemoresistance to temozolomide in human glioma cells.NVP-BEZ235,一种新型的双重 PI3K-mTOR 抑制剂,在人神经胶质瘤细胞中显示出抗神经胶质瘤活性,并降低替莫唑胺的化疗耐药性。
Cancer Lett. 2015 Oct 10;367(1):58-68. doi: 10.1016/j.canlet.2015.07.007. Epub 2015 Jul 15.
8
Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi-targeted kinase inhibitors in pimasertib-resistant human lung and colorectal cancer cells.帕米塞蒂布(一种选择性 MEK1/2 抑制剂)联合 PI3K/mTOR 抑制剂或多靶点激酶抑制剂在帕米塞蒂布耐药的人肺癌和结直肠癌细胞中的抗肿瘤活性。
Int J Cancer. 2013 Nov;133(9):2089-101. doi: 10.1002/ijc.28236. Epub 2013 May 29.
9
Discovery of CLKs inhibitors for the treatment of non-small cell lung cancer.发现 CLKs 抑制剂用于治疗非小细胞肺癌。
Eur J Med Chem. 2024 Dec 15;280:116952. doi: 10.1016/j.ejmech.2024.116952. Epub 2024 Oct 9.
10
Combined inhibition of AKT/mTOR and MDM2 enhances Glioblastoma Multiforme cell apoptosis and differentiation of cancer stem cells.联合抑制AKT/mTOR和MDM2可增强多形性胶质母细胞瘤细胞凋亡及癌症干细胞的分化。
Sci Rep. 2015 Apr 21;5:9956. doi: 10.1038/srep09956.

引用本文的文献

1
Mitochondrial CLK2 promotes chemotherapy resistance in colorectal Cancer by regulating oxidative phosphorylation and ferroptosis.线粒体CLK2通过调节氧化磷酸化和铁死亡促进结直肠癌的化疗耐药性。
J Mol Histol. 2025 Jul 23;56(4):239. doi: 10.1007/s10735-025-10533-0.
2
Forkhead box transcription factors (FOXOs and FOXM1) in glioma: from molecular mechanisms to therapeutics.胶质瘤中的叉头框转录因子(FOXOs和FOXM1):从分子机制到治疗学
Cancer Cell Int. 2023 Oct 11;23(1):238. doi: 10.1186/s12935-023-03090-7.
3
Cdc2-like kinases: structure, biological function, and therapeutic targets for diseases.Cdc2 样激酶:结构、生物学功能及疾病治疗靶点。
Signal Transduct Target Ther. 2023 Apr 7;8(1):148. doi: 10.1038/s41392-023-01409-4.
4
Temozolomide-induced guanine mutations create exploitable vulnerabilities of guanine-rich DNA and RNA regions in drug-resistant gliomas.替莫唑胺诱导的鸟嘌呤突变在耐药性脑胶质瘤中创造了富含鸟嘌呤的 DNA 和 RNA 区域可利用的弱点。
Sci Adv. 2022 Jun 24;8(25):eabn3471. doi: 10.1126/sciadv.abn3471. Epub 2022 Jun 22.
5
CPNE3 regulates the cell proliferation and apoptosis in human Glioblastoma via the activation of PI3K/AKT signaling pathway.CPNE3通过激活PI3K/AKT信号通路调节人胶质母细胞瘤中的细胞增殖和凋亡。
J Cancer. 2021 Oct 28;12(24):7277-7286. doi: 10.7150/jca.60049. eCollection 2021.
6
Dual-Specificity, Tyrosine Phosphorylation-Regulated Kinases (DYRKs) and cdc2-Like Kinases (CLKs) in Human Disease, an Overview.双特异性酪氨酸磷酸化调节激酶(DYRKs)和细胞分裂周期 2 样激酶(CLKs)在人类疾病中的作用概述。
Int J Mol Sci. 2021 Jun 3;22(11):6047. doi: 10.3390/ijms22116047.

本文引用的文献

1
Anti-tumor efficacy of a novel CLK inhibitor via targeting RNA splicing and MYC-dependent vulnerability.新型 CLK 抑制剂通过靶向 RNA 剪接和 MYC 依赖性脆弱性发挥抗肿瘤功效。
EMBO Mol Med. 2018 Jun;10(6). doi: 10.15252/emmm.201708289.
2
Preclinical therapeutic efficacy of a novel blood-brain barrier-penetrant dual PI3K/mTOR inhibitor with preferential response in PI3K/PTEN mutant glioma.一种新型血脑屏障穿透性双PI3K/mTOR抑制剂在PI3K/PTEN突变型神经胶质瘤中的临床前治疗疗效及优先反应
Oncotarget. 2017 Mar 28;8(13):21741-21753. doi: 10.18632/oncotarget.15566.
3
A Kinase Inhibitor Targeted to mTORC1 Drives Regression in Glioblastoma.一种靶向mTORC1的激酶抑制剂可促使胶质母细胞瘤消退。
Cancer Cell. 2017 Mar 13;31(3):424-435. doi: 10.1016/j.ccell.2017.01.014.
4
Cdc2-like kinase 2 is a key regulator of the cell cycle via FOXO3a/p27 in glioblastoma.在胶质母细胞瘤中,细胞周期蛋白依赖性激酶样激酶2通过FOXO3a/p27是细胞周期的关键调节因子。
Oncotarget. 2016 May 3;7(18):26793-805. doi: 10.18632/oncotarget.8471.
5
CLK2 inhibition ameliorates autistic features associated with SHANK3 deficiency.CLK2 抑制改善了与 SHANK3 缺乏相关的自闭症特征。
Science. 2016 Mar 11;351(6278):1199-203. doi: 10.1126/science.aad5487. Epub 2016 Feb 4.
6
Targeting RTK Signaling Pathways in Cancer.靶向癌症中的受体酪氨酸激酶信号通路
Cancers (Basel). 2015 Sep 3;7(3):1758-84. doi: 10.3390/cancers7030860.
7
Synergistic anticancer efficacy of MEK inhibition and dual PI3K/mTOR inhibition in castration-resistant prostate cancer.MEK抑制与双重PI3K/mTOR抑制在去势抵抗性前列腺癌中的协同抗癌疗效。
Prostate. 2015 Nov;75(15):1747-59. doi: 10.1002/pros.23057. Epub 2015 Aug 7.
8
Detection, Characterization, and Inhibition of FGFR-TACC Fusions in IDH Wild-type Glioma.异柠檬酸脱氢酶(IDH)野生型胶质瘤中FGFR-TACC融合蛋白的检测、特征分析及抑制作用
Clin Cancer Res. 2015 Jul 15;21(14):3307-17. doi: 10.1158/1078-0432.CCR-14-2199. Epub 2015 Jan 21.
9
Discovery of GSK2126458, a Highly Potent Inhibitor of PI3K and the Mammalian Target of Rapamycin.强效PI3K和雷帕霉素哺乳动物靶点抑制剂GSK2126458的发现
ACS Med Chem Lett. 2010 Jan 19;1(1):39-43. doi: 10.1021/ml900028r. eCollection 2010 Apr 8.
10
The somatic genomic landscape of glioblastoma.胶质母细胞瘤的体细胞基因组景观。
Cell. 2013 Oct 10;155(2):462-77. doi: 10.1016/j.cell.2013.09.034.